Mylan prasugrel 10 mg tablets recalled for failed dissolution testing
Mylan Pharmaceuticals is recalling Prasugrel 10mg tablets (Lot #3225272, expiring September 30, 2026) because they failed dissolution testing during 18-month stability studies. This means the tablets may not break down and release the medication as intended in the body. No injuries have been reported.
From the FDA notice · Read the official notice ↗ · All Mylan recalls
What to do
- Check if you have Prasugrel 10mg tablets with lot #3225272 and expiration date September 30, 2026.
- Contact your pharmacist or doctor before stopping the medication—do not stop taking it without medical guidance.
- Return affected bottles to your pharmacy or follow your doctor's instructions for safe disposal.
Is yours affected?
Compare your label or packaging with the recalled product.
- Product
- Prasugrel Tablets, USP, 10mg, Rx only, 30 Tablets in each bottle, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505, Made in India, NDC 0378-5186-93.
- Sold in
- Nationwide
- Made for
- Adults (0 months and older)
Details
- Units affected
- 47,662 bottles
- Illnesses reported
- None reported
- Manufactured in
- 3711 Collins Ferry Rd, N/A, Morgantown, WV, United States
- Classification
- Class II
- Recall number
- D-0839-2026
In the FDA's words
- Description
- Prasugrel Tablets, USP, 10mg, Rx only, 30 Tablets in each bottle, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505, Made in India, NDC 0378-5186-93. Failed Dissolution Specifications; product failed to meet 18-month stability testing acceptance criteria Lot #: 3225272, Exp. September 30, 2026 Distribution: Nationwide within the U.S Affected quantity: 47,662 bottles
- Hazard
- Failed Dissolution Specifications; product failed to meet 18-month stability testing acceptance criteria
More from Mylan
See all- Mylan Mycophenolate Mofetil injection recalled for failed dissolution specifications
ModerateFDASep 9, 2026
- Mylan acamprosate calcium tablets recalled for failed dissolution
ModerateFDAAug 26, 2026